Related references
Note: Only part of the references are listed.DPP-4 inhibitors in the treatment of type 2 diabetes
Helene Duez et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11
M. Jason Hatfield et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
Noriyasu Kato et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Global estimates of the prevalence of diabetes for 2010 and 2030
J. E. Shaw et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
Morali Sharma et al.
Therapeutics and Clinical Risk Management (2010)
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events
Bo Ahren
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tina Zerilli et al.
CLINICAL THERAPEUTICS (2007)
Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum
Kenji Masaki et al.
DRUG METABOLISM AND DISPOSITION (2007)
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug
Iskandar Idris et al.
DIABETES OBESITY & METABOLISM (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile)
I Brandt et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Type 2 diabetes: principles of pathogenesis and therapy
M Stumvoll et al.
LANCET (2005)
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
HJ Mest et al.
DIABETOLOGIA (2005)
Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease
AD Rule et al.
ANNALS OF INTERNAL MEDICINE (2004)
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Current management strategies for coexisting diabetes mellitus and obesity
AJ Scheen
DRUGS (2003)
Transport of cyclic nucleotides and estradiol 17-β-D-glueuronide by multidrug resistance protein 4 -: Resistance to 6-mercaptopurine and 6-thioguanine
ZS Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
